Originally reported by Hemp Industry Daily, the U.S. Drug Enforcement Administration (DEA) has elected to remove some forms of cannabidiol from the Schedule I drug classification. According to a report to be published tomorrow, “the Drug Enforcement Administration places certain drug products that have been approved by the Food and Drug Administration (FDA) and which contain cannabidiol (CBD) in schedule V of the Controlled Substances Act (CSA).” This specifically pertains to drugs including finished dosage formulations of CBD with a THC content below 0.1 percent.
This is the first time the DEA has removed any type of cannabis from Schedule I. This comes just three months after the FDA approved Epidiolex, a CBD-based drug used for rare forms of epilepsy. Without the DEA’s decision on Thursday, doctors would not be able to prescribe the medication as Schedule I drugs cannot be prescribed. Now, Epidiolex will be distributed through standard pharmaceutical channels, from a doctor’s prescription to a drug store, rather than through a dispensary or designated marijuana caregiver.
Read the full article: Cannabis & Tech Today
